x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

May 16, 2017 5:20 PM ET

BUYINS.NET: CYCC SqueezeTrigger Price is $5.25. There is $2,913,225 That Short Sellers Still Need To Cover.

Disclosure NewswireTM

iCrowdNewswire - May 16, 2017

May 16, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) in real time and just received an alert that CYCC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 554900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.25. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net .

From August 2009 to April 2017, an aggregate amount of 468297284 shares of CYCC have been shorted for a total dollar value of $2341486420. The CYCC SqueezeTrigger price of $5.25 is the volume weighted average price that all shorts are short in shares of CYCC. There is still approximately $2,913,225 of potential short covering in shares of CYCC.

Buyins.net has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.buyins.net .

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) – Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey..

The SqueezeTrigger database of billions of short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor – Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new “Fair Market Making Requirements”
Naked Shorts (RegSho) – Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

Earnings – Predicts probability, price move and length of move before and after all US stock earnings reports
Seasonality – Predicts probability, price move and length of move based on exact time of year for all US stocks
Group Correlation – Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups
SqueezeTrigger – Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Valuation – Tracks all known valuation models and applies them.
GATS – Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.
PatternScan – Automates tracking of every technical pattern and predicts next move in stocks.
Insider – Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders
Events – Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact:

Tom Ronk, CEO
BUYINS.NET
[email protected]
800-715-9999

Contact Information:

Tom Ronk, CEO
BUYINS.NET
[email protected]
800-715-9999

View Related News >